Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility

Area of Science:

• Pharmacology
• Gynecology
• Reproductive Medicine

Background:

• Selective progesterone receptor modulators (SPRMs) target the progesterone receptor (PR) with mixed agonist/antagonist properties.
• Progesterone plays a critical role in reproduction and reproductive tissues, making PR a key therapeutic target.
• SPRMs are being investigated for various gynecological conditions due to their mechanism of action.

Purpose of the Study:

• To review the efficacy and safety of SPRMs in treating gynecological conditions.
• To summarize the current evidence for SPRMs in uterine fibroids, endometriosis, endometrial cancer, breast cancer, and heavy menstrual bleeding.
• To highlight the potential and limitations of SPRMs in reproductive medicine.

Main Methods:

• Literature review of clinical trials and in vivo/in vitro studies on SPRMs.
• Analysis of data on compounds including mifepristone, ulipristal acetate, vilaprisan, asoprisnil, and telapristone.
• Evaluation of SPRM efficacy for specific gynecological conditions and associated side effects.

Main Results:

• SPRMs like mifepristone and ulipristal acetate show efficacy in uterine fibroids, endometriosis, and heavy menstrual bleeding.
• Limited success has been observed for SPRMs in endometrial cancer treatment.
• SPRMs demonstrate potential in PR-positive recurrent breast cancer and for emergency contraception.
• A common side effect is PR modulator-associated endometrial changes (PAECs).

Conclusions:

• SPRMs represent a promising class of drugs for managing several gynecological conditions.
• Further research is warranted to fully understand the therapeutic potential and safety profile of SPRMs.
• SPRMs have demonstrated clinical utility in specific gynecological applications, with ongoing investigations for others.